Drug Database
LI

Livact Jelly (Livact Jelly)

✓ Approved

Ajinomoto · therapeutic agent

What is Livact Jelly?

Livact Jelly is a therapeutic agent developed by Ajinomoto. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesLivact Jelly
CompanyAjinomoto
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ajinomoto

Therapeutic Indications

Livact Jelly is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Hepatobiliary disordersHepatic cirrhosis✓ Approved
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved

Related Research Articles

PubMedShock (Augusta, Ga.)2026-08-24

Mesenchymal Stem Cell Secretome Mitigates Inflammatory Endothelial Dysfunction.

Pokharel Marissa D MD, Osborn Baron K BK, Saviola Anthony J AJ, Maroney Sean P SP et al.

Endothelial cells (EC) dysfunction and barrier disruption are central drivers of inflammatory lung injury and adverse outcomes, yet targeted therapies remain lacking. We tested the hypothesis that a mesenchymal stem cell (MSC)-derived secretome can directly preserve EC function under inflammatory stress. We evaluated AlloEx (Vitro Biopharma), a Wharton's Jelly MSC-derived secretome enriched in bioactive RNAs, proteins, lipids, and extracellular vesicles with pro-reparative and immunomodulatory activity. Human lung microvascular endothelial cells (HLMVEC) were exposed to TNFα (4 h) with AlloEx administered 30 min before or after TNFα stimulation. EC thromboinflammatory gene expression was quantified by qPCR. Barrier integrity was assessed by transendothelial resistance (TEER) and VE-cadherin immunofluorescence. Mitochondrial function was evaluated using MitoSOX, TMRM, and mitochondrial fission imaging. Proteomic profiling was performed using trauma patient plasma as a clinically relevant inflammatory stimulus. AlloEx potently suppressed TNFα-induced EC activation, markedly reducing ICAM1, SELE, IL6, NOS3, ANG2, TEK, VEGFA, and F3 expression. Functionally, AlloEx rescued EC barrier integrity, preserving VE-cadherin localization at endothelial junctions and restoring TEER by 79% with pretreatment and 65% with post-treatment. Mechanistically, AlloEx prevented mitochondrial dysfunction, limiting reactive oxygen species generation, preserving membrane potential, and reducing fission. Proteomic profiling demonstrated that AlloEx induced coordinated remodeling of metabolic, vesicular, and inflammatory signaling pathways while suppressing cellular stress and pro-inflammatory signaling. These findings identify MSC-derived secretome therapy as a potent modulator of EC thromboinflammatory activation, barrier integrity, and mitochondrial function. AlloEx represents a promising, clinically translatable strategy to target EC dysfunction in inflammatory lung injury and trauma-associated endotheliopathy.

PMID 42635140
Read full article →
PubMedEuropean journal of pharmacology2026-08-21

10-Hydroxy-2-decenoic acid, a bioactive component of royal jelly, induces p53-Mediated apoptosis in cholangiocarcinoma in vitro and in vivo.

Yan Guohong G, Zhang Jiakao J, Lu Ziyan Z, Mo Shutian S et al.

The poor prognosis and limited treatment options for cholangiocarcinoma (CCA) continue to drive the search for novel therapeutics with clear mechanisms of action. 10-hydroxy-2-decenoic acid (10-HDA) is a unique bioactive fatty acid isolated from royal jelly, yet its therapeutic potential in CCA is unknown. In this study, we evaluated the anti-CCA properties of 10-HDA across cell-based, computational, transcriptomic, and animal models. Cell viability and clonogenic assays showed that 10-HDA strongly suppressed HUCCT1 and RBE cell growth by triggering extensive apoptosis. We also observed a marked decline in cell migration and invasion; rather than a purely targeted anti-metastatic effect, transcriptomic data suggested this motility loss is tightly linked to the drug's primary cytotoxicity and a parallel disruption of actin cytoskeleton dynamics. Computational predictions initially pointed toward apoptosis networks as primary targets, which was corroborated by our RNA-seq data highlighting a strong enrichment in both general apoptotic and specific TNF signaling pathways. Protein-level validation confirmed a dual-activation mechanism: 10-HDA upregulates the intrinsic p53/Bax axis while simultaneously engaging the extrinsic TNF/Caspase-8 cascade, both converging on Caspase-3 cleavage. These mechanisms translated effectively in vivo, where 10-HDA administration severely restricted xenograft tumor growth in nude mice without noticeable systemic toxicity. These findings identify 10-HDA as a potent, defined natural agent that halts CCA progression by activating comprehensive apoptotic programs.

PMID 42628622
Read full article →
PubMedInternational journal of stem cells2026-08-21

Therapeutic Effect of Pioglitazone-Pretreated Human Wharton's Jelly-Derived Mesenchymal Stem Cells in a Rat Tendon Injury Model.

Kim Won W, Kim Soo S, Lee Seul Ki SK, Kwon Young-Won YW et al.

The clinical application of mesenchymal stem cells (MSCs) has several limitations owing to their less therapeutic efficacy. Effect enhancement and MSCs from new sources might help in overcoming these limitations. The aim of the present study was to investigate the therapeutic effects of human Wharton's jelly-derived MSCs (hWJMSCs) and pioglitazone-pretreated MSCs (Pio-MSCs) in a rat tendon injury model. Fifty-four Sprague Dawley rats were randomly assigned to three groups: phosphate-buffered saline (PBS) group, implanted with PBS; MSC group, implanted with MSCs; and Pio-MSC group, implanted with Pio-MSCs. The cell or PBS with fibrin glue mixture was implanted around bilateral window defect in the Achilles tendons of the rats. The cross-sectional area measurement, histological analysis, gene expression, protein expression, and biomechanical analysis were performed at 2 and 4 weeks after modeling. Pio-MSC group revealed a significantly higher gene expression level of Col3 than PBS group at 2 weeks and that of TnC at 2 and 4 weeks. Moreover, MSC group revealed significantly higher gene expression level of Col1 than PBS group at 2 weeks. In general, the expression levels of Col1, Col3, Scx, and TnC were the highest in Pio-MSC group, followed by MSC and PBS groups. Furthermore, Pio-MSC group revealed significantly higher tenascin C-stained fraction than PBS group at 4 weeks. These findings suggest a potential role of hWJMSCs in tendon regeneration; however, the in vivo enhancement effect of pioglitazone pretreatment over MSC alone was not confirmed, and no differences were observed in histological or biomechanical outcomes among the groups.

PMID 42624828
Read full article →
PubMedPloS one2026-08-21

Microbiome modulation in regeneration in jellyfish.

Ohdera Aki A, Wang Matthew M, Mansbridge Maille M, Yu Changhua C et al.

The moon jelly Aurelia coerulea does not typically regenerate appendages. A previous study found that increasing nutrient availability promotes the activation of appendage regeneration. In this study, we found that changes in nutrient availability alter microbiome composition. Genome-scale metabolic modeling of the microbial symbionts suggests that the microbiome modulation reduces the abundance of a symbiont that competes with the host for metabolic resources. Antibiotic treatment that recapitulates the microbiome shift significantly promotes regeneration. Transcriptomic analysis of the host shows an upregulation of genes involved in the arginine biosynthetic pathway, including argininosuccinate synthase and carbamoyl phosphate synthase. Exogenous arginine supplementation promotes appendage regeneration. These findings suggest that microbiome composition, influenced by nutrient availability, contributes to the activation of host regeneration, and identify a role for arginine in promoting regeneration.

PMID 42627783
Read full article →
PubMedFrontiers in microbiology2026-08-21

Taxonomy and phylogeny of Dacrymyces (Dacrymycetales, Basidiomycota) with descriptions of a new species from China.

Liu Zhan-Bo ZB, Meng Ke-Ni KN, Zhang Jian-Ling JL, Fan Ying-Ge YG et al.

A new jelly fungus, Dacrymyces abaensis sp. nov., is described from the subalpine coniferous forests of Sichuan, China, based on morphology and ITS+nLSU phylogeny. The species grows on rotten wood of Picea and forms a distinct lineage within Dacrymyces. It is characterized by sessile, cerebriform, orange-yellow gelatinous basidiomata; subclavate probasidia (109-120 × 5.5-9 μm) that become bifurcate at maturity; clavate, thin-walled hyphidia (39-61 × 3.5-5.5 μm); and large, navicular basidiospores (36.6-56 × 11.9-15.6 μm) with up to 15 transverse septa and several longitudinal septa, germinating via conidia and germ tubes. A detailed description, illustrations, and the results of the phylogenetic analysis for the new species are provided. In addition, the new species is compared with closely related taxa.

PMID 42625764
Read full article →
PubMedJournal of liver cancer2026-08-21

SINEUP-mediated enhancement of HNF4α improves metabolic function in Huh7-based bioengineered hepatic microtissues.

Hashemian Zohreh Z, Zarrabi Morteza M, Nouri Masoumeh M, Piryaei Abbas A et al.

Human liver cell-based drug-screening platforms require stable hepatocyte identity and metabolic competence, but Huh7 cells show reduced hepatic function. We investigated whether SINEUP-mediated enhancement of hepatocyte nuclear factor 4 alpha (HNF4α) could improve the metabolic performance of Huh7-based three-dimensional hepatic microtissues. Decellularized liver extracellular matrix-derived microparticles were incorporated into three-dimensional microtissues containing Huh7 cells, human umbilical vein endothelial cells, and Wharton's jelly mesenchymal stem cells using AggreWell technology. Experimental microtissues were generated with Huh7 cells expressing a SINEUP-based long noncoding RNA targeting HNF4α and were compared with control microtissues. Enhanced HNF4α expression upregulated hepatic markers including HNF4α and albumin, decreased alpha-fetoprotein and CDH2, increased CDH1 expression, suppressed glycolytic genes, modulated lipid metabolism, and increased cytochrome P450-related gene expression. Albumin and fibrinogen secretion, urea synthesis, and glycogen storage increased, whereas alpha-fetoprotein secretion, lactate production, and cell migration decreased. SINEUP-mediated enhancement of HNF4α partially restored hepatocyte-like metabolic and functional properties in Huh7-based hepatic microtissues, supporting their potential use as an in vitro platform for drug discovery and toxicity screening.

PMID 42625329
Read full article →

+7468 more articles available with a free account

Sign up free to view all articles →

Ask about Livact Jelly